
Agency green light could help get medication off ASHP drug shortage list by reducing supply issues.

Agency green light could help get medication off ASHP drug shortage list by reducing supply issues.

The FDA has approved zanubrutinib (Brukinsa, BeiGene) for the treatment of adults with Waldenström macroglobulinemia (WM).

The findings from the phase 3 KEYNOTE-091 trial mark the first positive study for pembrolizumab in adjuvant stage IB-IIIA non-small cell lung cancer.

Amy Summers, consultant at Restore Health Consulting, discusses the proposed changed to the USP 795 and 797.

Evaluating the need to define and standardize how quality can be measured in pharmacy.

Approximately 400,000 women undergo breast implant surgeries each year in the United States, and selecting an implant is an important and personal part of the process.

Study results show health plans paid most of the drug costs, despite the lack of effect seen on COVID-19.

The World Health Organization issues a strong recommendation for baricitinib and a conditional one for sotrovimab.

Trastuzumab deruxtecan is a HER2-directed antibody drug conjugate being developed by both AstraZeneca and Daiichi Sankyo.

Monoclonal antibodies and emerging agents may avert severe illness, especially for high-risk individuals.

The Microbiome Health Index for post-Antibiotic dysbiosis was developed to improve the understanding of and manage the risks associated with antibiotic administration.

Pharmacies should address situations in which multiple bottles of tablets are used to refill a cassette.

The findings could help clinicians tailor the use of early antibiotics in newborns because only infants deemed at risk for infection should receive antibiotics.

Fostemsavir (Rukobia) is indicated in combination with other antiretroviral medications in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection.

A new analysis suggests that boosters can provide ongoing prevention of death and hospitalization.

Tisotumab vedotin-tftv is used as antitumor therapy for patients with disease progression during or after chemotherapy.

The observed increase in patient age at the time of relapse makes the findings even more impressive because longer survival is typically associated with younger age at the time of relapse.

Cabotegravir (Apretude) is indicated for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection.

Study results suggest that infection with Epstein-Barr virus may be the leading cause of multiple sclerosis.

C-CAR039 showed positive efficacy and safety data in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

There are many opportunities for pharmacists to hone and overcome their personal discomfort with exercising power and to broaden their repertoire of leadership skills.

Most pharmacists see a transition from transactional care to more direct patient care responsibilities.

Pharmacists should stay abreast of changes in formulations and recommendations, foster communication with their staff, and plan proactively.

Knocking down MAPK4 resulted in the cells’ increased sensitivity to PI3K inhibitors and reduced breast cancer growth.

This high efficacy and low toxicity allow the combination treatment to provide a significant quality-of-life benefit to patients.

Based on the results, the investigators found that a cloth face covering reduced emissions in all directions to about 2 feet compared to the 4 feet of emissions produced when coughing or speaking with no mask on.

Study data showed that increased levels of infection, inflammation, and metabolic alterations frequently observed in people with depression and psychosis may be a cause rather than a consequence of these disorders.

Germ cell tumors that occur in places other than the testicles and ovaries are very rare.

National Pharmacist Day is celebrated each year on January 12 and it is a chance to celebrate the incredible work that pharmacists do for their patients.

In a subset of 537 patients receiving the IV therapy across 178 clinics, there was a 54% response rate and 30% remission rate.